Breakthrough Isolaz Acne Therapy Featured In US
Aesthera Corporation's Isolaz painless acne therapy has been featured, issue of U.S. News & World Report, a leading national weekly news magazine. The publication describes Isolaz acne therapy as "an advance against acne" and reports that the Isolaz is the first treatment device FDA cleared to treat comedonal and pustular acne, in addition to mild to moderate, inflammatory acne and acne vulgaris.
Discussing clinical outcomes, the article explains the Isolaz system's effectiveness on patients of all ages, who have struggled with acne and have failed traditional therapies including topicals and antibiotics. Gilly Munavalli, MD, MHS, Director of Dermatology, Laser, and Veins Specialists of the Carolinas in Charlotte, NC and Clinical Instructor of Dermatology at Johns Hopkins University School of Medicine, notes that while the Isolaz also works on non-responders to traditional acne therapies, a greater benefit of the treatment is the rapid improvement relative to drugs.
The article describes a 22-year-old patient's struggle with acne and her 100% clinical, emotional and functional improvement post Isolaz treatments. Dermatologist Dale Isaacson, MD expresses great satisfaction with Isolaz system's efficacy noting that the device works in about 90% of his patients.
In addition to this breakthrough painless therapy for acne, Aesthera's Isolaz system is also FDA cleared to treat skin rejuvenation, including the treatment of vascular and pigmented lesions as well as hair removal on all skin types.
Prior to its coverage by U.S. News & World Report, Isolaz therapy has also been recently featured in the New York Times and Wall Street Journal. It has also been covered by Vogue, Elle, Allure, Shape, Bazaar, Self, and the June 2008 issues of Marie Claire and Family Circle, as a breakthrough acne treatment that also successfully and effectively minimizes and clears pores on a long-term basis.
Share this content.
Please include eMaxHealth in Google Alerts to receive tomorrow's stories and SHARE this with friends if it was interesting.